Search results

Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.

Result type

Technology appraisal guidance

Last updated

21 January 2016

Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.

Result type

Technology appraisal guidance

Last updated

26 June 2019

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Result type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.

Result type

Technology appraisal guidance

Published

28 July 2010

Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

Result type

Technology appraisal guidance

Last updated

27 November 2013

Discontinued Reference number: GID-TA10737

Result type

Technology appraisal guidance

Status

Discontinued

Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer in adults.

Result type

Technology appraisal guidance

Published

26 April 2006

Evidence-based recommendations on drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants. This involves draining excess CSF from the brain, washing out the blood, and breaking down blood clots using drugs (fibrinolytics).

Result type

HealthTech guidance

Published

23 November 2011

Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies.

Result type

Highly specialised technologies guidance

Last updated

19 April 2023

Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.

Result type

HealthTech guidance

Published

24 September 2008

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

Result type

Technology appraisal guidance

Published

27 April 2016

Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

Result type

Technology appraisal guidance

Published

23 March 2016

Evidence-based recommendations on bendamustine for treating chronic lymphocytic leukaemia in adults.

Result type

Technology appraisal guidance

Published

23 February 2011

Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.

Result type

Technology appraisal guidance

Published

28 June 2006